These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 21113210)
1. [Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus]. Pérez López G; González Albarrán O; Cano Megías M Nefrologia; 2010; 30(6):618-25. PubMed ID: 21113210 [TBL] [Abstract][Full Text] [Related]
2. [Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus]. Mauricio D Med Clin (Barc); 2013 Sep; 141 Suppl 2():31-5. PubMed ID: 24444522 [TBL] [Abstract][Full Text] [Related]
3. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697 [TBL] [Abstract][Full Text] [Related]
4. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Ghezzi C; Loo DDF; Wright EM Diabetologia; 2018 Oct; 61(10):2087-2097. PubMed ID: 30132032 [TBL] [Abstract][Full Text] [Related]
5. [Introduction]. García SD Med Clin (Barc); 2013 Sep; 141 Suppl 2():1-2. PubMed ID: 24444516 [No Abstract] [Full Text] [Related]
6. [Renal SGLT2 inhibitors: a new type of oral anti-hyperglycemia drugs]. Zhang WB; Gong N; Wang YX Sheng Li Ke Xue Jin Zhan; 2010 Dec; 41(6):453-6. PubMed ID: 21416966 [No Abstract] [Full Text] [Related]
7. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Neumiller JJ; White JR; Campbell RK Drugs; 2010 Mar; 70(4):377-85. PubMed ID: 20205482 [TBL] [Abstract][Full Text] [Related]
8. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment]. Girard J Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741 [TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Scheen AJ Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697 [TBL] [Abstract][Full Text] [Related]
10. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes. Davidson JA; Kuritzky L Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933 [TBL] [Abstract][Full Text] [Related]
11. A new class of drug for the management of type 2 diabetes: sodium glucose co-transporter inhibitors: 'glucuretics'. Chan HW; Ashan B; Jayasekera P; Collier A; Ghosh S Diabetes Metab Syndr; 2012; 6(4):224-8. PubMed ID: 23199545 [TBL] [Abstract][Full Text] [Related]
12. A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition. Basile J Postgrad Med; 2011 Jul; 123(4):38-45. PubMed ID: 21680987 [TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes. Demaris KM; White JR Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409 [TBL] [Abstract][Full Text] [Related]
14. The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment. Andrianesis V; Doupis J Expert Rev Clin Pharmacol; 2013 Sep; 6(5):519-39. PubMed ID: 23978089 [TBL] [Abstract][Full Text] [Related]
15. Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events. Packer M Circulation; 2019 Aug; 140(6):443-445. PubMed ID: 31381418 [No Abstract] [Full Text] [Related]
16. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Calado J IDrugs; 2009 Dec; 12(12):785-98. PubMed ID: 19943222 [TBL] [Abstract][Full Text] [Related]
17. [Contribution of the kidney to glucose homeostasis]. Segura J; Ruilope LM Med Clin (Barc); 2013 Sep; 141 Suppl 2():26-30. PubMed ID: 24444521 [TBL] [Abstract][Full Text] [Related]
18. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778 [TBL] [Abstract][Full Text] [Related]
19. The role of the kidney in hyperglycemia: a new therapeutic target in type 2 diabetes mellitus. Hinnen D J Cardiovasc Nurs; 2013; 28(2):157-65. PubMed ID: 22343215 [TBL] [Abstract][Full Text] [Related]
20. SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes. Kilov G; Leow S; Thomas M Aust Fam Physician; 2013 Oct; 42(10):706-10. PubMed ID: 24130972 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]